{
  "hypotheses": [
    {
      "id": "H1",
      "prediction": "IF HK-II is displaced from VDAC1 (via methyl jasmonate or clotrimazole) in immune-cold cancer cell lines with high baseline f_HKII (>0.6), THEN cytoplasmic mtDNA levels increase \u22653-fold within 6h, phospho-STING (Ser366) increases \u22652-fold by 12h, and IFN-\u03b2 secretion increases \u22655-fold by 24h, compared to vehicle control.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "f_HKII_baseline",
          "unit": "dimensionless",
          "low": 0.5,
          "high": 0.9,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "mtDNA_fold_change",
          "unit": "fold",
          "low": 1.0,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "STING_fold_change",
          "unit": "fold",
          "low": 1.0,
          "high": 8.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "\u03b2_fold_change",
          "unit": "fold",
          "low": 1.0,
          "high": 50.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "time_to_peak_STING",
          "unit": "hours",
          "low": 4.0,
          "high": 24.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 9.0,
      "experimental_protocol": "Use Panc-1 (pancreatic, immune-cold archetype, high HK-II/VDAC1) and A375 (melanoma, moderate HK-II) cell lines. Treat with methyl jasmonate (0.5-3 mM) or clotrimazole (10-50 \u03bcM) for 6/12/24h. Measure cytoplasmic mtDNA by qPCR after digitonin fractionation, p-STING by Western blot, IFN-\u03b2 by ELISA, and VDAC1 oligomerization by EGS crosslinking + native PAGE. Include HK-II siRNA as genetic control. Timeline: 4 weeks.",
      "expected_outcome": "HK-II displacement causes",
      "null_outcome": "HK-II displacement does not increase cytoplasmic mtDNA or p-STING, or mtDNA increases but cGAS-STING remains silent, indicating the coupling is not through VDAC1 oligomerization.",
      "dose_ranges": {
        "Methyl jasmonate": {
          "doses": [
            500.0,
            1000.0,
            2000.0,
            3000.0
          ],
          "unit": "\u03bcM;"
        },
        "Clotrimazole": {
          "doses": [
            10.0,
            20.0,
            35.0,
            50.0
          ],
          "unit": "\u03bcM;"
        },
        "II siRNA": {
          "doses": [
            10.0,
            25.0,
            50.0
          ],
          "unit": "nM"
        }
      },
      "readouts": [
        "qPCR (ND1",
        "ND5 mtDNA genes in cytoplasmic fraction)",
        "Western blot (p-STING S366",
        "p-TBK1",
        "p-IRF3)",
        "ELISA (IFN-\u03b2",
        "CXCL10)",
        "native PAGE with EGS crosslinking (VDAC1 oligomers)",
        "co-IP (HK-II:VDAC1)",
        "Seahorse (glycolytic shift confirmation)"
      ],
      "controls": [
        "Vehicle (DMSO)",
        "scrambled siRNA",
        "STING inhibitor H-151 (epistasis control)",
        "DNase I cytoplasmic pre-treatment (confirms mtDNA dependency)",
        "VDAC1-KO cells (specificity control)",
        "---",
        "##"
      ]
    },
    {
      "id": "H2",
      "prediction": "IF a composite gate-jamming score (GJS = f_HKII \u00d7 0.4 + f_BclxL \u00d7 0.3 + [Chol/CL] \u00d7 0.3, normalized) is computed across \u226515 cancer cell lines, THEN GJS correlates inversely with basal cGAS-STING pathway activity (p-STING, ISG expression) with Spearman \u03c1 \u2264 \u22120.6 (p<0.01), and lines with GJS >0.7 show \u226580% concordance with immune-cold classification (low MHC-I, low CXCL10).",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "f_HKII",
          "unit": "dimensionless",
          "low": 0.1,
          "high": 0.9,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "f_BclxL",
          "unit": "dimensionless",
          "low": 0.05,
          "high": 0.7,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "ISG_score",
          "unit": "arbitrary",
          "low": 0.0,
          "high": 100.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 7.0,
      "experimental_protocol": "Select 15-20 cell lines spanning tumor types (e.g., Panc-1, MDA-MB-231, A549, HCT116, SK-MEL-28, MCF7, PC3, U87, HepG2, NCI-H460, B16F10, 4T1, CT26, MC38, LLC). Quantify HK-II:VDAC1 co-IP (f_HKII), Bcl-xL:VDAC1 co-IP (f_BclxL), mitochondrial cholesterol and cardiolipin by mass spectrometry. Simultaneously measure p-STING, ISG panel (qPCR: IFIT1, MX1, OAS1, ISG15), surface MHC-I (flow cytometry), CXCL10 (ELISA). Compute GJS, correlate. Timeline: 8 weeks.",
      "expected_outcome": "Strong inverse correlation between GJS and immune signaling metrics. Cell lines cluster into gate-jammed/immune-cold vs. gate-open/immune-hot groups. Pancreatic and certain lung lines show highest GJS; colorectal lines like MC38 show lowest.",
      "null_outcome": "No significant correlation between GJS and immune metrics, or high-GJS lines show active cGAS-STING, indicating gate-jamming is not the dominant determinant of immune visibility.",
      "dose_ranges": {},
      "readouts": [
        "Co-immunoprecipitation + densitometry (f_HKII",
        "f_BclxL)",
        "LC-MS/MS lipidomics (Chol",
        "CL from mitochondrial fractions)",
        "Western blot (p-STING",
        "STING",
        "cGAS)",
        "RT-qPCR (ISG panel)",
        "flow cytometry (HLA-ABC/MHC-I)",
        "ELISA (CXCL10",
        "IFN-\u03b2)"
      ],
      "controls": [
        "Recombinant IFN-\u03b2 treatment (positive control for ISG induction capacity)",
        "STING agonist diABZI (confirms pathway competence per line)",
        "mitochondrial fraction purity verified by Tom20+/calreticulin\u2212",
        "---",
        "##"
      ]
    },
    {
      "id": "H3",
      "prediction": "IF immune-cold syngeneic tumors (4T1 or B16F10, predicted high GJS) are treated with gate-restoring combination (HK-II displacer + Bcl-xL inhibitor) followed by anti-PD-1, THEN tumor growth inhibition shows synergy (combination index <0.7 by Bliss independence) with \u226550% tumor volume reduction vs. anti-PD-1 alone, while immune-hot tumors (MC38, predicted low GJS) show no additional benefit from gate-restoration beyond anti-PD-1 alone.",
      "source_claims": [],
      "key_variables": [],
      "parameters": [
        {
          "name": "tumor_volume_reduction",
          "unit": "%",
          "low": 30.0,
          "high": 80.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "CD8_TIL_fold_increase",
          "unit": "fold",
          "low": 2.0,
          "high": 10.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "combination_index_Bliss",
          "unit": "(uniform,",
          "low": 0.3,
          "high": 1.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "gate_restoration_lead_time",
          "unit": "days",
          "low": 2.0,
          "high": 7.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        },
        {
          "name": "survival_extension",
          "unit": "%",
          "low": 20.0,
          "high": 100.0,
          "distribution": "uniform",
          "mean": null,
          "std": null
        }
      ],
      "testability_score": 7.0,
      "experimental_protocol": "Implant 4T1 (immune-cold) and MC38 (immune-hot) tumors in BALB/c and C57BL/6 mice respectively (n=10/group). Groups: (1) vehicle, (2) gate-restoration combo (methyl jasmonate 100mg/kg IP + ABT-263/navitoclax 50mg/kg PO, days 5-12), (3) anti-PD-1 (200\u03bcg IP, days 8,11,14), (4) gate-restoration + anti-PD-1. Measure tumor volume q2d, sacrifice day 21 for TIL analysis (flow: CD8+, CD4+, NK), intratumoral cytokines (multiplex), and tumor mtDNA cytoplasmic fraction. Timeline: 10 weeks including breeding/acclimation.",
      "expected_outcome": "In 4T1: gate-restoration alone modestly slows growth; anti-PD-1 alone fails; combination produces dramatic regression with synergistic CI<0.7, increased CD8+ TILs, elevated intratumoral IFN-\u03b2. In MC38: anti-PD-1 alone effective; gate-restoration adds no benefit, confirming specificity to immune-cold context.",
      "null_outcome": "No synergy in 4T1 (combination no better than additive), or gate-restoration + anti-PD-1 works equally in MC38, indicating the mechanism is not specific to gate-jamming status.",
      "dose_ranges": {
        "Methyl jasmonate": {
          "doses": [
            50.0,
            100.0,
            150.0
          ],
          "unit": "mg/kg"
        }
      },
      "readouts": [
        "Caliper tumor measurement",
        "survival (Kaplan-Meier)",
        "flow cytometry on dissociated tumors (CD45+CD3+CD8+",
        "CD4+",
        "NK1.1+",
        "Granzyme B+",
        "PD-1+)",
        "multiplex cytokine (IFN-\u03b2",
        "CXCL10",
        "TNF-\u03b1",
        "IL-12)",
        "qPCR cytoplasmic mtDNA from sorted tumor cells",
        "IHC (CD8",
        "p-STING)"
      ],
      "controls": [
        "Isotype control antibody (rat IgG2a)",
        "STING-KO host mice (to confirm cGAS-STING dependency)",
        "heat-killed tumor cell vaccination (confirms antigenicity exists)",
        "navitoclax alone (Bcl-xL inhibition without HK-II displacement)",
        "---",
        "##"
      ]
    }
  ],
  "n_hypotheses": 3,
  "total_calls": 1,
  "latency_s": 54.56
}